Cargando…

Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial

BACKGROUND AND OBJECTIVE: Most evidence suggests that the pharmacokinetics of monoclonal antibodies (mAbs) are not meaningfully altered by patient characteristics, including racial/ethnic differences. Nevertheless, the pharmacokinetic profile of eptinezumab has not been evaluated in a Chinese popula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xue-Ning, Xu, Hong-Rong, Cui, Ellen, Petersen, Kamilla Buchberg, Ryding, Janka, Ettrup, Anders, Østergaard, Jette Buch, Larsen, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632206/ https://www.ncbi.nlm.nih.gov/pubmed/37917246 http://dx.doi.org/10.1007/s40261-023-01315-1

Ejemplares similares

Eptinezumab for migraine prevention in patients 50 years or older
por: Martin, Vincent, et al.
Publicado: (2022)

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
por: McAllister, Peter, et al.
Publicado: (2022)

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
por: Blumenfeld, Andrew, et al.
Publicado: (2022)

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
por: Pozo-Rosich, Patricia, et al.
Publicado: (2022)

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
por: Ashina, Messoud, et al.
Publicado: (2022)

Eptinezumab for migraine
Publicado: (2022)

Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
por: Cady, Roger, et al.
Publicado: (2022)

Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies
por: Smith, Timothy R., et al.
Publicado: (2021)

Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine
por: Baker, Brian, et al.
Publicado: (2020)

Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study
por: Barbanti, Piero, et al.
Publicado: (2022)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2022)

A Review of Eptinezumab Use in Migraine
por: Datta, Abhigyan, et al.
Publicado: (2021)

Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2023)

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
por: McAllister, Peter, et al.
Publicado: (2022)

Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab
por: Limberg, Nicole
Publicado: (2023)

Population Pharmacokinetic Meta-Analysis of Vortioxetine in Healthy Individuals
por: Areberg, Johan, et al.
Publicado: (2014)

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
por: Lipton, Richard B., et al.
Publicado: (2020)

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients
por: Baker, Brian, et al.
Publicado: (2021)

Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
por: Scuteri, Damiana, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants
por: Li, Wan-Zhen, et al.
Publicado: (2021)

The eptinezumab:CGRP complex structure – the role of conformational changes in binding stabilization
por: David, Laurent, et al.
Publicado: (2021)

Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects
por: Yang, Meng-Jie, et al.
Publicado: (2020)

Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men
por: Wilson, Sue, et al.
Publicado: (2015)

Acanthoecid choanoflagellates from the Atlantic Arctic Region − a baseline study
por: Thomsen, Helge Abildhauge, et al.
Publicado: (2017)

Pharmacokinetic Study of Enteric-Coated Sustained-Release Aspirin Tablets in Healthy Chinese Participants
por: Cong, Duanduan, et al.
Publicado: (2023)

Pharmacokinetics of Diazepam and Its Metabolites in Urine of Chinese Participants
por: Wang, Le-le, et al.
Publicado: (2022)

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
por: Buse, Dawn C., et al.
Publicado: (2022)

Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study
por: Bader, Yazan, et al.
Publicado: (2023)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
por: Altamura, Claudia, et al.
Publicado: (2023)

Becoming the kind of doctor that you want to be. A qualitative study about participation in Balint group work
por: Ryding, Elsa Lena, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants
por: Johansson, Susanne, et al.
Publicado: (2022)

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
por: Ashina, Messoud, et al.
Publicado: (2020)

Status migrainosus inpatient treatment with eptinezumab (SMITE): study protocol for a randomised controlled trial
por: Ray, Jason Charles, et al.
Publicado: (2022)

Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants
por: Perera, Vidya, et al.
Publicado: (2022)

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
por: Humeniuk, Rita, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pbcn0bcbhj1502fcsqs1lair7b